Conv. Plasma
Nigella Sativa
Peg.. Lambda

All ivermectin studies
Meta analysis
Home COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Discharge 87% primary Improvement Relative Risk Ivermectin  Chahla et al.  EARLY TREATMENT  RCT Is early treatment with ivermectin beneficial for COVID-19? RCT 254 patients in Argentina (September 2020 - January 2021) Higher discharge with ivermectin (p=0.004) Chahla et al., Research, Society and D.., Mar 2021 Favors ivermectin Favors control

Randomized trials - Ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers

Chahla et al., Research, Society and Development, doi:10.33448/rsd-v11i8.30844 (date from preprint), NCT04784481
Mar 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Cluster RCT outpatients in Argentina showing significantly faster recovery with ivermectin. There were no deaths. Cluster RCT where outpatients in Tucumán were assigned to the ivermectin group and outpatients from San Miguel de Tucumán and Gran San Miguel de Tucumán were assigned to the control group. All comorbidities, percentage of male patients, and age were higher in the ivermectin group, favoring the control group.
This is the 22nd of 46 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.
This is the 46th of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion).
risk of no discharge, 86.9% lower, RR 0.13, p = 0.004, treatment 2 of 110 (1.8%), control 20 of 144 (13.9%), NNT 8.3, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, logistic regression, multivariable, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chahla et al., 30 Mar 2021, Cluster Randomized Controlled Trial, Argentina, peer-reviewed, 9 authors, study period September 2020 - January 2021, dosage 24mg days 1, 8, 15, 22, trial NCT04784481 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Randomized trials - Ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers
Rossana Elena Chahla, Luis Medina Ruiz, Teresa Mena, Yolanda Brepe, Paola Terranova, Eugenia Silvana Ortega, Guillermo Gabriel Barrenechea, Daniel Gustavo Goroso, María De Los Ángeles Peral De Bruno
Research, Society and Development, doi:10.33448/rsd-v11i8.30844
Randomized trials -Ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers Ensaio aleatório -Reutilização de Ivermectina para tratamento COVID-19 de pacientes ambulatórios com doença leve em centros primários de saúde Ensayos aleatorios -Reutilización de la Ivermectina para el tratamiento con COVID-19 de pacientes ambulatorios con enfermedad leve en centros de atención primaria
Declarations Ethics approval and consent to participate The people who agreed to participate in the study gave their informed consent before starting the study. The protocol was approved by Independent Ethical Committee / Health Research Directorate, Ministry of Health, Tucumán Government, Argentina, IRB: 054/2020 in accordance with the ReNIS, National Register in Health Research, Argentina /0032. Consent for publication "Not applicable" Conflict of Interests The authors did not receive any monetary compensation for this work. They declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Authors' contributions ESO supervised the database. GGB, ESO and DGG contributed with the data processing and contributed to the statistical analysis. ESO, DGG and MPB were responsible for writing the manuscript. TM, YB and PT contributed to data collection. REC and LMR were the institutional managers to carry out the work. MPB supervised the project.
Ashburn, Thor, Drug repositioning: identifying and developing new uses for existing drugs, Nature Reviews Drug Discovery, doi:10.1038/nrd1468
Bottan, Vera-Cossio, Hoffmann, The unequal impact of the coronavirus pandemic: evidence of seventeen development countries
Bryant, Lawrie, Dowswell, Fordham, Mitchell et al., Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001442
Caly, Druce, Catton, Jans, Wagsta, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Research
Caly, Wagstaff, Jans, Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?, Antiviral Research
Carvallo, Hirsch, Alkis, Contreras, Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel, Journal of Biomedical Research and Clinical Investigation
Carvallo, Hirsch, Farinella, Safety and efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID 19, medRxiv the preprint server for health sciences, doi:10.1101/2020.09.10.20191619
Cassará, Ivermectina asociada a iota-Carragenina aplicada localmente en la cavidad bucal, en la profilaxis de la enfermedad COVID-19 en el personal de salud, Estudio IVERCAR01
Chaccour, Casellas, Blanco-Di Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedicine
Chahla, Medina Ruiz, Mena, Cluster Randomised Trials -Ivermectin Repurposing for COVID-19 Treatment of Outpatient with Mild Disease in Primary Health Care Centers, doi:10.1101/2021.03.29.21254554v1
Chahla, Medina Ruiz, Mena, Cluster Randomised Trials -Ivermectin Repurposing for COVID-19 Treatment of Outpatient with Mild Disease in Primary Health Care Centers, doi:10.21203/
Chahla, Medina Ruiz, Mena, Cluster Randomised Trials -Ivermectin Repurposing for COVID-19 Treatment of Outpatient with Mild Disease in Primary Health Care Centers, doi:10.21203/
Chahla, Medina Ruiz, Ortega, Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment with Ivermectin and Iotacarrageenan (Ivercar-Tuc), American Journal of Therapeutics
Chong, Sullivan, New uses for old drugs, Nature, doi:10.1038/448645a
Dyall, Coleman, Hart, Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection, Antimicrobial Agents and Chemotherapy
Edwards, Dingsdale, Helsby, Orme, Breckenridge, The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution, European Journal of Clinical Pharmacology, doi:10.1007/BF00637608
Elgazzar, Hany, Youssef, Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic, Research Square, doi:10.21203/
Krolewiecki, Lifschitz, Moragas, Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial, SSRN Electronic Journal, doi:10.2139/ssrn.3714649
Lima-Morales, Méndez-Hernández, Flores, Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico, International Journal of Infectious Diseases
Liu, Fang, Reagan, In silico drug repositioning-what we need to know, Drug Discovery Today
López-Medina, López, Hurtado, Effect of Ivermectin on Time to Resolution of Symptoms Among Adults with Mild COVID-19: A Randomized Clinical Trial, Journal American Medical Association
Marshall, Murthy, Diaz, A minimal common outcome measure set for COVID-19 clinical research, Lancet Infectious Diseases
Mayer, Krolewiecki, Ferrero, Bocchio, Barbero et al., Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients, Frontiers in Public Health, doi:.10.3389/fpubh.2022.813378
Neil, Fenton, Kow, Hasan, Popp et al., Bayesian hypothesis testing and hierarchical modeling of ivermectin effectiveness, American Journal of Therapeutics, doi:CD015017.10.1097/MJT.0000000000001450
Osterberg, Blaschke, Adherence to Medication, The New England Journal of Medicine
Padhi, Pati, Panda, Effect of ivermectin in the treatment of COVID-19: a trial sequential analysis highlighted the requirement of additional randomized controlled trials, Clinical Infectious Diseases, doi:ciab692.10.1093/cid/ciab692
Rodríguez Chamorro, García-Jiménez, Amariles, Rodríguez Chamorro, Faus, Revisión de tests de medición del cumplimiento terapéutico utilizados en la práctica clínica, Atención primaria, doi:10.1157/13125407
Roman, Burela, Pasupuleti, Piscoya, Vidal et al., Ivermectin for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials, Clinical of Infectious Diseases
Rubin, Crowe, COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings
Wu, Mc Googan, Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention, Journal American Medical Association
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop